ArticleCancer medicine2026
Arteannuin B Inhibits NSCLC Cells via Regulating miR-194-3p/CLDN2 Axis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Arteannuin B (Art B), a sesquiterpene lactone from Artemisia annua, combats non-small cell lung cancer (NSCLC) chemoresistance by activating a novel miR-194-3p/CLDN2 axis, as identified here through integrated transcriptomic and functional analyses. Here, we combined transcriptomic profiling with functional validation to identify claudin-2 (CLDN2) as a critical mediator of Art B's anticancer effects in NSCLC. CLDN2, significantly upregulated in NSCLC tissues versus paired normal tissues, promoted tumor cell proliferation and cisplatin resistance by upregulating multidrug resistance-associated protein 2 (MRP2). Mechanistically, miR-194-3p directly binds to two conserved sites (nt 358-365 and 1232-1238) within the CLDN2 3' UTR, suppressing its expression via mRNA degradation and translational inhibition, thereby attenuating proliferation and resensitizing cells to cisplatin. Importantly, Art B exerted antitumor effects by upregulating miR-194-3p, which subsequently inhibited CLDN2. This study not only elucidates a previously unrecognized mechanism for overcoming chemoresistance but also nominates CLDN2 as a prognostic biomarker, offering a promising therapeutic strategy that could benefit NSCLC patients facing treatment failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.